Loading clinical trials...
Loading clinical trials...
Drug therapy of atypical parkinsonism is generally considered either ineffective or minimal 1. Therefore, there is an urgent need to find alternative therapies to treat atypical parkinsonian disorders...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of California, Los Angeles
NCT06508801 · Parkinson's Disease and Parkinsonism
NCT07442370 · Parkinson Disease, Parkinsonism
NCT05962489 · Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, and more
NCT05121012 · Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
NCT04715399 · Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), and more
UCLA
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions